公开(公告)号：US12084489B2

公开(公告)日：2024-09-10

申请号：US17052470

申请日：2019-05-02

申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services ,  The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

发明人： Masaru Kanekiyo ,  Michael Gordon Joyce ,  Wei Bu ,  Jeffrey I. Cohen ,  Yaroslav Tsybovsky

IPC分类号： C07K16/08 ,  A61K47/68 ,  C12Q1/70 ,  G01N33/569

CPC分类号： C07K16/085 ,  A61K47/6803 ,  A61K47/6839 ,  C12Q1/705 ,  G01N33/56994 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q2600/158 ,  G01N2333/05 ,  G01N2800/26

摘要： Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.

公开(公告)号：US20230348568A1

公开(公告)日：2023-11-02

申请号：US17800706

申请日：2021-02-19

申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services

发明人： Jeffrey I. Cohen ,  Wei Bu ,  Nathan Board ,  Kennichi Dowdell

IPC分类号： C07K16/08 ,  C12N15/63 ,  G01N33/569 ,  A61P31/20

CPC分类号： C07K16/085 ,  C12N15/63 ,  G01N33/56994 ,  A61P31/20 ,  C07K2317/565 ,  C07K2317/94 ,  C07K2317/31

摘要： Monoclonal antibodies that specifically bind gp42 of Epstein-Barr virus (EBV) are described. The antibodies are capable of blocking fusion of EBV-infected cells and neutralizing EBV infection. Use of the EBV-specific monoclonal antibodies, and conjugates thereof, for the treatment and prophylaxis of EBV infection is also described.

公开(公告)号：US20180321223A1

公开(公告)日：2018-11-08

申请号：US15772319

申请日：2016-10-26

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Centre National de la Recherche Scientifique - CNR ,  Universite Paul Sabatier Toulouse III ,  Universite Paris Diderot - Paris 7

发明人： Nabila Jabrane-Ferrat ,  Johan Siewiera ,  Reem Al-Daccak

IPC分类号： G01N33/50 ,  C12Q1/6886 ,  A61P31/18 ,  A61P31/16 ,  C07K16/24

CPC分类号： G01N33/5023 ,  A61P31/16 ,  A61P31/18 ,  C07K16/244 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/56966 ,  G01N33/56972 ,  G01N33/56988 ,  G01N33/56994 ,  G01N33/574 ,  G01N2800/245 ,  G01N2800/26 ,  G01N2800/50 ,  G01N2800/52

摘要： The invention relates to a method for monitoring the immunological profile of a subject, comprising measuring the expressions of each member of the group consisting of NKp30a, NKp30b, NKp30c, NKp44b and NKp44c, in a biological sample of said subject, wherein: if the expressions of NKp30a, NKp30b, and NKp44b are the three highest among said group, then said subject has a responsive profile; or if the expressions of NKp30c and NKp44c are the two highest among said group, then said subject has an unresponsive profile.

公开(公告)号：US20180031556A1

公开(公告)日：2018-02-01

申请号：US15549443

申请日：2016-01-26

申请人： XIAMEN UNIVERSITY

发明人： Shengxiang GE ,  Jinjie LI ,  Xi HUANG ,  Tingdong LI ,  Jun ZHANG ,  Ningshao XIA

IPC分类号： G01N33/569

CPC分类号： G01N33/56983 ,  G01N33/53 ,  G01N33/543 ,  G01N33/569 ,  G01N33/56994 ,  G01N2333/045 ,  G01N2469/20 ,  G01N2800/50 ,  G01N2800/52

摘要： The invention belongs to the fields of medicine and immunology, particularly, the field of immunological diagnosis. In particular, the invention discloses a method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection and a kit therefore. The method comprises the steps of: (1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and (2) comparing the level with a predetermined reference value, wherein if the level is below the predetermined reference value, the subject is determined to be at risk of developing HCMV active infection. In addition, the invention also discloses a method for screening a candidate drug which is capable of improving the ability of a subject to resist human cytomegalovirus (HCMV) active infection, and a kit therefore.

公开(公告)号：US20170189517A1

公开(公告)日：2017-07-06

申请号：US15116968

申请日：2015-02-06

申请人： VALORISATION-HSJ, LIMITED PARTNERSHIP ,  VAROLISATION-RECHERCHE, LIMITED PARTNERSHIP

发明人： CAROLINE ALFIERI ,  JEROME TANNER ,  JING HU ,  JURGEN SYGUSCH ,  MATHIEU COINÇON

IPC分类号： A61K39/12 ,  G01N33/569 ,  C07K16/08 ,  G01N33/68

CPC分类号： A61K39/12 ,  C07K16/085 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2710/16222 ,  C12N2710/16234 ,  G01N33/56994 ,  G01N33/6854 ,  G01N2469/20

摘要： The present invention relates to a peptide comprising (A) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence PDDRTLQ (SEQ ID NO:1); and (ii) a second domain covalently linked to the first domain and comprising an amino acid sequence having at least 60% sequence similarity with the sequence QNPVYLIPETVPYIKWDN (SEQ ID NO:2) or (B) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence GSAKPGNGSYF (SEQ ID NO: 41); and (ii) a second domain covalently linked to the first domain, said second domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence SVKTEMLGNEID (SEQ ID NO: 42), wherein the peptide binds to monoclonal antibody clone 72A1. This peptide may be useful for inducing the production of neutralizing antibodies against a gp350-expressing herpesvirus, such as Epstein-Barr virus (EBV), for example for immunizing or vaccinating an animal against a gp350-expressing herpesvirus, as well as for detecting the presence or absence neutralizing anti-gp350-expressing herpesvirus antibodies in a sample.

公开(公告)号：US20170146534A1

公开(公告)日：2017-05-25

申请号：US14926989

申请日：2015-10-29

申请人： CFS, LLC ,  Ohio State University

发明人： A. Martin LERNER ,  Ronald M. GLASER

IPC分类号： G01N33/569

CPC分类号： G01N33/56994 ,  A61K31/52 ,  A61K31/522 ,  A61K31/662 ,  A61K31/7056 ,  G01N2333/05 ,  Y02A50/401 ,  Y02A50/402 ,  Y02A50/57

摘要： A method of diagnosing a subset of Epstein Barr Virus, Myalgic Encephalomyelitis Chronic Fatigue Syndrome (ME/CFS) patients through a multi-prong clinical/serological analysis is provided wherein Epstein Barr Virus Abortive Lytic Replication (EBV) is determined as the specific causal agent through the use of serum antibodies to EBV encoded dUTPase and serum antibodies to EBV DNA Polymerase as molecular markers. A method of treating patients diagnosed with Epstein Barr Virus Abortive Lytic Replication (EBV), Myalgic Encephalomyelitis Chronic Fatigue Syndrome (ME/CFS) with specific antiviral nucleosides is also provided, to alleviate the condition.

公开(公告)号：US09562232B2

公开(公告)日：2017-02-07

申请号：US14563512

申请日：2014-12-08

申请人： University of Massachusetts

发明人： Timothy F. Kowalik ,  Mariluz Rodriguez-Gonzalez ,  Alexander Lagadinos

IPC分类号： C12N15/11 ,  C12N15/113 ,  A61K31/522 ,  A61K31/7105 ,  A61K35/50 ,  A61K45/06 ,  C12Q1/70

CPC分类号： C12N15/1133 ,  A61K31/522 ,  A61K31/7105 ,  A61K35/50 ,  A61K45/06 ,  C12N15/1131 ,  C12N2310/11 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/315 ,  C12N2320/31 ,  C12Q1/705 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/56994 ,  G01N2333/03 ,  A61K2300/00

摘要： The present invention related to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates expression of miR145 target genes, including IRS-1. Transfection of cells with a miR145 agent, such as a miR145 mimetic, reduces HCMV replication and protein expression. miR132 and miR212 are upregulated in cells infected with HCMV. This upregulation modulates expression of miR132 and miR212 target genes, including MeCP2 and RICS. Transfection of cells with a miR132 and/or a miR212 antagonist reduces HCMV replication and protein expression. Accordingly, the invention provides methods of attenuating HCMV replication by modulating, for example, miR145, miR132, and/or miR212, and targets thereof. Also provided are methods of detecting an HCMV infection, and compositions and kits useful for attenuating HCMV replication.

摘要翻译： 本发明涉及miR145，miR132，miR212以及由这些miRNA调节的基因或基因产物。 miR145在感染HCMV的细胞中下调。 这种下调调节miR145靶基因的表达，包括IRS-1。 用miR145试剂（例如miR145模拟物）转染细胞可降低HCMV复制和蛋白质表达。 miR132和miR212在用HCMV感染的细胞中上调。 这种上调调节miR132和miR212靶基因的表达，包括MeCP2和RICS。 用miR132和/或miR212拮抗剂转染细胞减少HCMV复制和蛋白质表达。 因此，本发明提供了通过调节例如miR145，miR132和/或miR212及其靶标来减弱HCMV复制的方法。 还提供了检测HCMV感染的方法，以及用于减轻HCMV复制的组合物和试剂盒。

公开(公告)号：US20170028058A1

公开(公告)日：2017-02-02

申请号：US15201783

申请日：2016-07-05

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Feng Yao

IPC分类号： A61K39/245 ,  C12N7/00

CPC分类号： A61K39/245 ,  A61K35/763 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/57 ,  C12N7/00 ,  C12N15/869 ,  C12N15/8695 ,  C12N2710/16011 ,  C12N2710/16021 ,  C12N2710/16034 ,  C12N2710/16062 ,  C12N2710/16071 ,  C12N2710/16611 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2710/16661 ,  C12N2710/16662 ,  C12N2830/003 ,  C12N2830/006 ,  G01N33/56994

摘要： The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.

摘要翻译： 本发明涉及可用于免疫患者的生殖器疱疹疫苗的单纯疱疹病毒2型病毒。

公开(公告)号：US09529976B2

公开(公告)日：2016-12-27

申请号：US14479241

申请日：2014-09-05

申请人： Theranos, Inc.

发明人： Clarissa Lui ,  Elizabeth A. Holmes

IPC分类号： C12Q1/68 ,  C12Q1/70 ,  C12P19/34 ,  G01N33/569 ,  G06F19/00

CPC分类号： G16H10/40 ,  C12Q1/68 ,  C12Q1/6806 ,  C12Q1/6844 ,  C12Q1/689 ,  C12Q1/6893 ,  C12Q1/6895 ,  C12Q1/70 ,  C12Q1/701 ,  C12Q1/703 ,  C12Q1/705 ,  C12Q1/706 ,  C12Q1/707 ,  C12Q2521/501 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/56911 ,  G01N33/56916 ,  G01N33/56938 ,  G01N33/56944 ,  G01N33/56983 ,  G01N33/56988 ,  G01N33/56994 ,  G01N35/10 ,  G01N2035/00237 ,  G01N2333/11 ,  G01N2469/10 ,  G01N2469/20 ,  G06F19/00 ,  G06F19/3456 ,  G16H20/10 ,  G16H50/20 ,  Y02A50/58 ,  Y02A90/24 ,  Y02A90/26 ,  Y10T436/11

摘要： Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.

公开(公告)号：US20150204876A1

公开(公告)日：2015-07-23

申请号：US14416890

申请日：2013-07-23

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE DE NANTES ,  CHU NANTES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) ,  UNIVERSITE D'ANGERS

发明人： Edith Bigot-Corbel ,  Sylvie Hermouet ,  Delphine Feron ,  Cathy Charlier ,  Pierre Weigel ,  Adrien Herlédan ,  Yannick Jacques

IPC分类号： G01N33/577 ,  B01J19/00

CPC分类号： G01N33/577 ,  B01J19/0046 ,  G01N33/56905 ,  G01N33/56922 ,  G01N33/56972 ,  G01N33/56994 ,  G01N33/57426 ,  G01N33/5767 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2333/045 ,  G01N2333/05 ,  G01N2333/186 ,  G01N2333/205 ,  G01N2333/45 ,  G01N2800/22 ,  G01N2800/52 ,  G01N2800/60 ,  Y02A50/57

摘要： The present invention concerns materials and methods for characterizing monoclonal immunoglobulin specificity of a Monoclonal Gammopathy of Undetermined Significance (MGUS) or Myeloma patients using a protein microarray comprising (a) a substrate, (b) antigens immobilized on the substrate, said antigens being selected from a defined group consisting of infectious agent antigens and/or self-antigens. In particular said protein microarray may be used to improve diagnosis, for the prognosis of myeloma or MGUS, for preventing transformation of MGUS toward myeloma, for adapting treatment of MGUS and myeloma or for monitoring the response to therapy of MGUS and myeloma patients.

摘要翻译： 本发明涉及用于鉴定包含（a）底物，（b）固定在底物上的抗原，蛋白质微阵列，所述抗​​原选自下列物质的蛋白质微阵列的，用于表征未确定意义的单克隆丙种球蛋白病（MGUS）或骨髓瘤患者的单克隆丙种球蛋白病特异性的单克隆免疫球蛋白特异性的材料和方法 由感染性抗原和/或自身抗原组成的定义的组。 特别地，所述蛋白质微阵列可用于改善骨髓瘤或MGUS的预后，用于预防MGUS向骨髓瘤转化，适应MGUS和骨髓瘤的治疗或用于监测MGUS和骨髓瘤患者的治疗反应。